Profile data is unavailable for this security.
About the company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
- Revenue in CHF (TTM)58.79bn
- Net income in CHF10.62bn
- Incorporated1966
- Employees103.61k
- LocationRoche Holding AGGrenzacherstrasse 124BASEL 4002SwitzerlandCHE
- Phone+41 9 732354295
- Websitehttps://www.roche.com/
Mergers & acquisitions
| Acquired company | ROG:SWX since announced | Transaction value |
|---|---|---|
| LumiraDx International Ltd | 4.27% | -- |
| LumiraDx Group Ltd | 4.27% | 295.00m |
| Carmot Therapeutics Inc | 5.51% | 3.10bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Co | 42.40bn | -6.49bn | 106.72bn | 34.10k | -- | 6.96 | 40.65 | 2.52 | -3.60 | -3.60 | 23.38 | 8.45 | 0.513 | 3.97 | 5.12 | 1,391,056.00 | -7.84 | 3.05 | -10.45 | 3.76 | 75.87 | 76.13 | -15.28 | 7.69 | 1.09 | 11.30 | 0.7431 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Sanofi SA | 45.50bn | 4.20bn | 110.09bn | 87.99k | 25.92 | -- | 17.57 | 2.42 | 3.60 | 3.60 | 39.01 | -- | -- | -- | -- | 555,219.70 | -- | 5.87 | -- | 7.16 | 69.33 | 68.78 | 9.44 | 16.90 | -- | 42.73 | -- | 60.51 | 2.32 | 5.42 | -35.49 | 4.57 | 8.87 | 4.14 |
| Pfizer Inc | 53.73bn | 3.82bn | 129.93bn | 88.00k | 34.48 | 1.57 | 12.98 | 2.42 | 0.7438 | 0.7399 | 10.57 | 16.29 | 0.2767 | 1.60 | 4.71 | 683,079.60 | 1.98 | 8.20 | 2.39 | 10.40 | 70.82 | 69.34 | 7.16 | 22.68 | 0.729 | -- | 0.4225 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 29.08bn | 3.78bn | 141.51bn | 26.70k | 37.69 | 21.03 | 16.15 | 4.87 | 7.82 | 7.82 | 60.33 | 14.00 | 0.3587 | 2.08 | 4.83 | 1,218,502.00 | 4.66 | 10.36 | 5.87 | 13.06 | 60.48 | 75.41 | 13.00 | 26.51 | 0.9553 | 2.62 | 0.8892 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| AstraZeneca plc | 45.78bn | 5.81bn | 182.70bn | 89.90k | 31.70 | 5.02 | 17.54 | 3.99 | 3.32 | 3.32 | 26.15 | 20.96 | 0.5095 | 1.67 | 4.42 | 454,543.00 | 6.47 | 3.34 | 8.88 | 4.61 | 82.15 | 79.64 | 12.69 | 7.69 | 0.7133 | 9.00 | 0.4361 | 143.06 | 3.29 | 15.71 | 81.11 | 22.54 | 22.47 | 1.10 |
| Novartis AG | 44.63bn | 10.51bn | 206.82bn | 76.06k | 18.41 | 4.88 | 13.79 | 4.63 | 5.13 | 7.65 | 21.76 | 19.36 | 0.4619 | 2.16 | 6.76 | 586,814.90 | 10.87 | 8.53 | 16.86 | 11.23 | 74.99 | 72.93 | 23.54 | 22.68 | 0.9002 | 14.72 | 0.4248 | 67.20 | 7.57 | 0.2779 | 41.64 | -7.71 | 0.7808 | 6.19 |
| Roche Holding AG | 58.79bn | 10.62bn | 209.11bn | 103.61k | 19.23 | 7.00 | 14.07 | 3.56 | 13.23 | 13.23 | 73.21 | 36.32 | 0.6526 | 1.88 | 5.05 | 567,395.40 | 12.76 | 16.12 | 19.22 | 25.24 | 73.71 | 71.48 | 19.55 | 22.98 | 0.9656 | 17.08 | 0.5116 | 58.80 | -7.21 | 0.6494 | -7.43 | 1.90 | -1.13 | 1.99 |
| Merck & Co Inc | 56.47bn | 10.86bn | 224.26bn | 72.00k | 20.80 | 5.64 | 15.27 | 3.97 | 4.77 | 4.77 | 24.95 | 17.58 | 0.5634 | 2.39 | 5.80 | 877,416.70 | 10.85 | 7.70 | 14.19 | 10.29 | 76.59 | 72.26 | 19.25 | 15.03 | 1.15 | 24.33 | 0.4611 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| AbbVie Inc | 49.64bn | 4.54bn | 279.50bn | 50.00k | 61.73 | 51.84 | 23.14 | 5.63 | 2.87 | 2.87 | 31.32 | 3.41 | 0.3972 | 4.31 | 4.85 | 1,110,660.00 | 3.67 | 6.55 | 5.09 | 8.40 | 67.25 | 69.74 | 9.24 | 16.46 | 0.5419 | 7.88 | 0.9213 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Nov 2024 | 25.37m | 3.61% |
| UBS Asset Management Switzerland AGas of 05 Nov 2024 | 24.27m | 3.46% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 19.81m | 2.82% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 13.92m | 1.98% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Sep 2024 | 9.64m | 1.37% |
| Geode Capital Management LLCas of 21 Nov 2024 | 7.51m | 1.07% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 6.53m | 0.93% |
| BlackRock Asset Management Deutschland AGas of 08 Nov 2024 | 4.43m | 0.63% |
| MFS International (UK) Ltd.as of 31 Oct 2024 | 4.29m | 0.61% |
| Dodge & Coxas of 30 Sep 2024 | 4.22m | 0.60% |
